[Comment] Finding the right combination antiviral therapy for influenza

Influenza results in annual epidemics and global pandemics of acute respiratory illness that increases morbidity, mortality, and hospital admissions. Fortunately, there are currently two classes of antivirals licensed for the treatment of influenza in much of the world: the M2 inhibitiors (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir, peramivir and zanamivir). There are also other antivirals licensed in Asia (laninamivir and favipiravir) and Russia (umifenovir). Additionally, a wide range of novel antivirals have been or are being studied in the treatment of influenza.

Original Article: [Comment] Finding the right combination antiviral therapy for influenza

More From BioPortfolio on "[Comment] Finding the right combination antiviral therapy for influenza"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications